tolvaptan has been researched along with Chronic Disease in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Decaux, G; Gankam Kengne, F | 1 |
| Fujimoto, K; Fujiwara, R; Horio, T; Izumiya, Y; Kasayuki, N; Matsuoka, Y; Nakamura, H; Nakao, K; Sakamoto, Y; Yokouchi, G; Yoshimura, R; Yoshiyama, M | 1 |
| Li, G; Liu, R; Ma, Z; Wang, W; Yuan, M; Zhang, K; Zhang, Y | 1 |
| Imamura, T; Kinugawa, K | 1 |
| Gao, WQ; Meng, XD; Sun, Z | 1 |
| Filmyer, DM; Geboy, AG; Josiassen, RC; Shaughnessy, RA | 1 |
| Adhiyaman, V; Chattopadhyay, I; Williams, M | 1 |
| Czerwiec, FS; Ellison, H; Hobart, M; Krasa, H; Ouyang, J; Verbalis, JG | 1 |
| Laczi, F | 1 |
| Whellan, DJ | 1 |
| Lindenfeld, J | 1 |
| Huynh-Do, U; Stober, CN | 1 |
| Greenberg, A; Lehrich, RW | 1 |
| Berl, T; Bichet, DG; Czerwiec, FS; Ouyang, J; Quittnat-Pelletier, F; Schrier, RW; Verbalis, JG | 1 |
| Afdhal, NH; Cárdenas, A; Czerwiec, F; Ginès, P; Guevara, M; Marotta, P; Oyuang, J | 1 |
| Curtis, JL; Czerwiec, F; Filmyer, DM; Geboy, AG; Josiassen, RC; Ouyang, J; Shaughnessy, RA; Skuban, N | 1 |
| Hensen, J | 1 |
| Berl, T; Jovanovich, AJ | 1 |
| Czerwiec, F; Gheorghiade, M; Kambayashi, J; Niazi, I; Orlandi, C; Ouyang, J; Zampino, M | 1 |
| Fujiki, H; Kinoshita, S; Miyazaki, T; Mori, T; Nakamura, S; Nakayama, S; Onogawa, T; Yamamura, Y | 1 |
| Batlle, D; Chen, S; Jalandhara, N | 1 |
| Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
| Schweiger, TA; Zdanowicz, MM | 1 |
10 review(s) available for tolvaptan and Chronic Disease
| Article | Year |
|---|---|
Hypertonic saline, isotonic saline, water restriction, long loops diuretics, urea or vaptans to treat hyponatremia.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Bicarbonates; Chronic Disease; Drinking; Humans; Hyponatremia; Practice Guidelines as Topic; Saline Solution; Saline Solution, Hypertonic; Sodium; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Urea; Uric Acid | 2020 |
Update of acute and long-term tolvaptan therapy.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Chronic Disease; Heart Failure; Humans; Japan; Time Factors; Tolvaptan | 2019 |
Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Body Weight; Chronic Disease; Heart Failure; Humans; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Sodium; Tolvaptan; Urine | 2019 |
[Etiology, diagnostics and therapy of hyponatremias].
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Blood Volume; Brain Diseases; Central Nervous System; Chronic Disease; Demeclocycline; Demyelinating Diseases; Diagnosis, Differential; Diuretics; Extracellular Fluid; Furosemide; Humans; Hyponatremia; Inappropriate ADH Syndrome; Lithium Compounds; Morpholines; Osmolar Concentration; Osmosis; Pyrroles; Severity of Illness Index; Sodium; Spiro Compounds; Time Factors; Tolvaptan; Vasopressins | 2008 |
[Treating hyponatraemia--not an easy task].
Topics: Administration, Oral; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Brain Edema; Chronic Disease; Clinical Trials as Topic; Female; Humans; Hyponatremia; Inpatients; Magnetic Resonance Imaging; Myelinolysis, Central Pontine; Sodium; Sodium Chloride; Time Factors; Tolvaptan; Tomography, X-Ray Computed | 2009 |
[Hyponatremia : The water-intolerant patient].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Brain Edema; Chronic Disease; Diagnosis, Differential; Hyponatremia; Inappropriate ADH Syndrome; Infusions, Intravenous; Intensive Care Units; Neurologic Examination; Prognosis; Risk Factors; Saline Solution, Hypertonic; Survival Analysis; Tolvaptan | 2012 |
Where vaptans do and do not fit in the treatment of hyponatremia.
Topics: Acute Disease; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Chronic Disease; Drug Costs; Hormone Antagonists; Humans; Hyponatremia; Receptors, Vasopressin; Sodium; Tolvaptan; Treatment Outcome | 2013 |
Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyponatremia; Male; Prognosis; Receptors, Vasopressin; Risk Assessment; Severity of Illness Index; Tolvaptan; Treatment Outcome; Water-Electrolyte Imbalance | 2007 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
6 trial(s) available for tolvaptan and Chronic Disease
| Article | Year |
|---|---|
Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Hyponatremia; Male; Middle Aged; Pilot Projects; Severity of Illness Index; Tolvaptan | 2016 |
Pharmacotherapy of acute and chronic heart failure: part 2.
Topics: Acute Disease; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tolvaptan; Treatment Outcome | 2009 |
Oral tolvaptan is safe and effective in chronic hyponatremia.
Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Female; Humans; Hyponatremia; Male; Middle Aged; Tolvaptan | 2010 |
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Chronic Disease; Female; Health Surveys; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recurrence; Sodium; Tolvaptan; Treatment Outcome | 2012 |
Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.
Topics: Administration, Oral; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Hyponatremia; Long-Term Care; Male; Middle Aged; Psychotic Disorders; Sodium; Tolvaptan; Treatment Outcome | 2012 |
Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Weight; Chronic Disease; Diuretics; Double-Blind Method; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Hyponatremia; Male; Middle Aged; Osmolar Concentration; Sodium; Tolvaptan; Treatment Outcome; Urinalysis; Water-Electrolyte Balance | 2003 |
7 other study(ies) available for tolvaptan and Chronic Disease
| Article | Year |
|---|---|
Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Glomerular Filtration Rate; Heart Failure; Humans; Outpatients; Retrospective Studies; Tolvaptan | 2021 |
Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats.
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Remodeling; Chronic Disease; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Heart Atria; Heart Rate; Hypoxia; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 9; MicroRNAs; Rats, Sprague-Dawley; Signal Transduction; Tolvaptan | 2018 |
Reconsidering chronic hyponatremia in psychosis.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Diagnosis, Differential; Humans; Hyponatremia; Natriuretic Agents; Patient Selection; Psychotic Disorders; Severity of Illness Index; Sodium; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2013 |
Once-weekly tolvaptan for chronic symptomatic hyponatremia due to syndrome of inappropriate secretion of anti-diuretic hormone.
Topics: Aged, 80 and over; Benzazepines; Chronic Disease; Drug Administration Schedule; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Tolvaptan | 2014 |
Introduction: Vasopressin therapy.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Heart Failure; Humans; Hyponatremia; Sodium; Tolvaptan; Vasopressins | 2009 |
Treatment of chronic hyponatremia: now we know how, but do we know when or if?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Humans; Hyponatremia; Tolvaptan | 2010 |
Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia.
Topics: Acute Disease; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Water; Brain; Chronic Disease; Diuresis; Hyponatremia; Male; Organ Size; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sodium; Tolvaptan; Urine | 2005 |